The DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening
Open accessAbstract
BACKGROUND: Down's syndrome occurs when a person has three copies of chromosome 21 (or the specific area of chromosome 21 implicated in causing Down's syndrome) rather than two. It is the commonest congenital cause of mental disability. Non-invasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing. Before agreeing to screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test. This includes subsequent choices for further tests they may face, and the implications of both false positive (i.e. invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal) and false negative screening tests (i.e. a fetus with Down's syndrome will be missed). The decisions that may be faced by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes of screening can be associated with considerable physical and psychological morbidity. No screening test can predict the severity of problems a person with Down's syndrome will have. OBJECTIVES: To estimate and compare the accuracy of first and second trimester serum markers with and without first trimester ultrasound markers for the detection of Down's syndrome in the antenatal period, as combinations of markers. SEARCH METHODS: We conducted a sensitive and comprehensive literature search of MEDLINE (1980 to 25 August 2011), Embase (1980 to 25 August 2011), BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), the Database of Abstracts of Reviews of Effectiveness (the Cochrane Library 25 August 2011), MEDION (25 August 2011), the Database of Systematic Reviews and Meta-Analyses in Laboratory Medicine (25 August 2011), the National Research Register (Archived 2007), and Health Services Research Projects in Progress database (25 August 2011). We did not apply a diagnostic test search filter. We did forward citation searching in ISI citation indices, Google Scholar and PubMed 'related articles'. We also searched reference lists of retrieved articles SELECTION CRITERIA: Studies evaluating tests of combining first and second trimester maternal serum markers in women up to 24 weeks of gestation for Down's syndrome, with or without first trimester ultrasound markers, compared with a reference standard, either chromosomal verification or macroscopic postnatal inspection. DATA COLLECTION AND ANALYSIS: Data were extracted as test positive/test negative results for Down's and non-Down's pregnancies allowing estimation of detection rates (sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS criteria. We used hierarchical summary ROC meta-analytical methods to analyse test performance and compare test accuracy. Analysis of studies allowing direct comparison between tests was undertaken. We investigated the impact of maternal age on test performance in subgroup analyses. MAIN RESULTS: Twenty-two studies (reported in 25 publications) involving 228,615 pregnancies (including 1067 with Down's syndrome) were included. Studies were generally high quality, although differential verification was common with invasive testing of only high risk pregnancies. Ten studies made direct comparisons between tests. Thirty-two different test combinations were evaluated formed from combinations of eight different tests and maternal age; first trimester nuchal translucency (NT) and the serum markers AFP, uE3, total hCG, free βhCG, Inhibin A, PAPP-A and ADAM 12. We looked at tests combining first and second trimester markers with or without ultrasound as complete tests, and we also examined stepwise and contingent strategies.Meta-analysis of the six most frequently evaluated test combinations showed that a test strategy involving maternal age and a combination of first trimester NT and PAPP-A, and second trimester total hCG, uE3, AFP and Inhibin A significantly outperformed other test combinations that involved only one serum marker or NT in the first trimester, detecting about nine out of every 10 Down's syndrome pregnancies at a 5% false positive rate. However, the evidence was limited in terms of the number of studies evaluating this strategy, and we therefore cannot recommend one single screening strategy. AUTHORS' CONCLUSIONS: Tests involving first trimester ultrasound with first and second trimester serum markers in combination with maternal age are significantly better than those without ultrasound, or those evaluating first trimester ultrasound in combination with second trimester serum markers, without first trimester serum markers. We cannot make recommendations about a specific strategy on the basis of the small number of studies available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–246 of 246
Comparison between disclosure and non-disclosure approaches for trisomy 21 screening tests
Herman, A. (2002) · Human Reproduction · doi:10.1093/humrep/17.5.1358 · Cited by 17
Cheng, P., Chu, D., Chueh, H., See, L., Chang, H.-C., & Weng, D. R. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(03)00948-7 · Cited by 17
Measurement of Nuchal Translucency and the Prenatal Diagnosis of Down Syndrome
Saucedo, M., DeVigan, C., Vodovar, V., Lelong, N., Goffinet, F., & Khoshnood, B. (2009) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181b6f251 · Cited by 16
Canini, S., Prefumo, F., Famularo, L., Venturini, P. L., Palazzese, V., & Biasio, P. D. (2002) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2002.103 · Cited by 16
Yamamoto, R., Azuma, M., Hoshi, N., Kishida, T., Satomura, S., & Fujimoto, S. (2001) · Human Reproduction · doi:10.1093/humrep/16.11.2438 · Cited by 16
Schmidt, P. M., Rom, J., Maul, H., Vaske, B., Hillemanns, P., & Scharf, A. (2007) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-007-0324-6 · Cited by 16
Maternal serum ADAM12s as a potential marker of trisomy 21 prior to 10 weeks of gestation
Spencer, K., Vereecken, A. J., & Cowans, N. J. (2008) · Prenatal Diagnosis · doi:10.1002/pd.1939 · Cited by 16
Stressig, R., Kozlowski, P., Froehlich, S., Siegmann, H. J., Hammer, R., Blumenstock, G., & Kagan, K. O. (2010) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.7749 · Cited by 15
Early first‐trimester maternal serum placental growth factor in trisomy 21 pregnancies
Cowans, N. J., Stamatopoulou, A., Tørring, N., & Spencer, K. (2010) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.8890 · Cited by 15
Schmidt, P. M., STABOULIDOU, I., Soergel, P., Wüstemann, M., Hillemanns, P., & Scharf, A. (2007) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-006-0288-y · Cited by 15
Gebb, J. S., & Dar, P. (2009) · Prenatal Diagnosis · doi:10.1002/pd.2157 · Cited by 15
Integrated Screening for Down's Syndrome
Jenkins, T. M., & Wapner, R. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412513 · Cited by 15
Nuchal Translucency Thresholds in Prenatal Screening for Down Syndrome and Trisomy 18
Miron, P., Côté, Y. P., & Lambert, J. (2009) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)34121-4 · Cited by 14
Li, R., Hui, P. W., Tang, M. H. Y., Lau, E. T. K., Yeung, W. S. B., Ho, P. C., & Ng, E. H. Y. (2010) · Prenatal Diagnosis · doi:10.1002/pd.2455 · Cited by 14
Papadopoulou, E., Sifakis, S., Giahnakis, E., Fragouli, Y. G., Karkavitsas, N. S., Koumantakis, E. E., & Kalmanti, M. (2008) · Fetal Diagnosis and Therapy · doi:10.1159/000116743 · Cited by 13
Maternal serum levels of total activin‐A in first‐trimester trisomy 21 pregnancies
Spencer, K., Liao, A. W., Skentou, H., Ong, C. Y. T., & Nicolaides, K. H. (2001) · Prenatal Diagnosis · doi:10.1002/pd.53 · Cited by 13
Maymon, R., Dreazen, E., Bukovsky, I., Weinraub, Z., & Herman, A. (2001) · Prenatal Diagnosis · doi:10.1002/pd.61 · Cited by 13
[First trimester diagnosis of chromosomal defects].
Nicolaides, K. H., & Węgrzyn, P. (2005) · PubMed · Cited by 11
A novel method for the detection of down syndrome with the use of four serum markers
Azuma, M., Yamamoto, R., Wakui, Y., Minobe, S., Satomura, S., & Fujimoto, S. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.123201 · Cited by 11
The effect of fetal gender on second‐trimester maternal serum inhibin‐A concentration
Lam, Y. H., & Tang, M. H. Y. (2001) · Prenatal Diagnosis · doi:10.1002/pd.120 · Cited by 11
First-trimester screening: lessons from clinical trials and implementation
Koos, B. J. (2006) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/01.gco.0000192966.29449.01 · Cited by 11
Odibo, A. O., Schoenborn, J. A., Haas, K., & Macones, G. A. (2009) · Prenatal Diagnosis · doi:10.1002/pd.2323 · Cited by 11
Schmidt, P. M., Hörmansdörfer, C., Golatta, M., & Scharf, A. (2009) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-009-1137-6 · Cited by 11
Combining first and second trimester markers for Down syndrome screening: Think twice
Cocciolone, R., Brameld, K., O'Leary, P. C., Haan, E., Müller, P., & Shand, K. L. (2008) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2008.00911.x · Cited by 10
The NTplus method of screening for Down syndrome: achieving the 2010 targets?
Habayeb, O. M. H., Goodburn, S. F., Chudleigh, T., BROCKELSBY, J. C., Missfelder‐Lobos, H., Hackett, G. A., & Lees, C. C. (2010) · Prenatal Diagnosis · doi:10.1002/pd.2488 · Cited by 10
Results and Views of Women in Population-Wide Pregnancy Screening for Trisomy 21 in East Finland
Heikkilä, A., Ryynänen, M., Kirkinen, P. P., & Saarikoski, S. (2009) · Fetal Diagnosis and Therapy · doi:10.1159/000264439 · Cited by 10
Rode, L., Wøjdemann, K. R., Shalmi, A. C., Larsen, S. O., Sundberg, K., Nørgaard‐Pedersen, B., Christiansen, M., & Tabor, A. (2003) · Prenatal Diagnosis · doi:10.1002/pd.648 · Cited by 10
Schmidt, P. M., Pruggmayer, M., Steinborn, A., Schippert, C., STABOULIDOU, I., Hillemanns, P., & Scharf, A. (2007) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-007-0342-4 · Cited by 10
Urine tests for Down's syndrome screening
Alldred, S. K., Guo, B., Takwoingi, Y., Pennant, M. E., Wisniewski, S., Deeks, J. J., Neilson, J. P., & Alfirević, Ž. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011984 · Cited by 10
Self-citationMyrick, J. E., Caudill, S. P., Il, H., Mk, R., Mj, A., & Pueschel, S. M. (1990) · PubMed · Cited by 10
Smith, E. R., Petersen, J. L., Okorodudu, A. O., & Bissell, M. G. (1996) · Cited by 10
Lüthgens, K. (2008) · Fetal Diagnosis and Therapy · doi:10.1159/000165116 · Cited by 9
Aneuploidy screening: ultrasound versus biochemistry
Sabrià, J., Cabrero, D., & Bach, C. (2002) · The ultrasound review of obstetrics & gynecology/Ultrasound review of obstetrics and gynecology · doi:10.1080/14722240208500490 · Cited by 9
Anuwutnavin, S., Wanitpongpan, P., & Chanprapaph, P. (2009) · PubMed · Cited by 9
Correlations between first and second trimester markers for Down's syndrome screening
Campogrande, M., Viora, E., Errante, G., Bastonero, S., Sciarrone, A., Pirrone, P. G., Perona, M., Mancini, G., Dall'Amico, D., Pavanello, E., et al. (2001) · Journal of Medical Screening · doi:10.1136/jms.8.3.163 · Cited by 9
Jorgez, C. J., Dang, D., Wapner, R. J., Farina, A., Simpson, J. L., & Bischoff, F. Z. (2007) · Human Reproduction · doi:10.1093/humrep/dem154 · Cited by 9
Nuchal translucency screening: how do women actually utilize the results?
Caughey, A. B., Musci, T. J., Belluomini, J., Main, D. M., Otto, C., & Goldberg, J. (2006) · Prenatal Diagnosis · doi:10.1002/pd.1617 · Cited by 9
Nuchal translucency as a method of first-trimester screening for aneuploidy.
Naidoo, P., Erasmus, I., Jeebodh, J., Nicolaou, E., & Gelderen, C. J. V. (2008) · PubMed · Cited by 8
Miron, P., Lambert, J., Marcil, A., Cowans, N. J., Stamatopoulou, A., & Spencer, K. (2010) · Prenatal Diagnosis · doi:10.1002/pd.2441 · Cited by 7
Herman, A., Dreazen, E., Tovbin, Y., Reish, O., Bukovsky, I., & Maymon, R. (2003) · Fetal Diagnosis and Therapy · doi:10.1159/000069377 · Cited by 7
New ultrasonographic markers of aneuploidies: nasal bones
Monni, G., & Zoppi, M. A. (2002) · The ultrasound review of obstetrics & gynecology/Ultrasound review of obstetrics and gynecology · doi:10.1080/14722240208500480 · Cited by 7
Maternal serum analyte levels in pregnancies with fetal Down syndrome resulting from translocations
Saller, D. N., Canick, J. A., Kellner, L. H., et al. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70287-4 · Cited by 7
Ozkaya, O., Sezik, M., Özbaşar, D., & Kaya, H. (2010) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(10)60031-9 · Cited by 6
Petersen, J. R., Smith, E., Okorodudu, A. O., & Bissell, M. G. (1996) · PubMed · Cited by 6
First trimester ultrasound screening of chromosomal abnormalities
Trninić-Pjević, A., & Novakov-Mikić, A. S. (2007) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh0704153t · Cited by 5
Optimal crown–rump length for measuring the nuchal translucency
Wax, J. R., Pinette, M. G., Cartin, A., & Blackstone, J. A. (2007) · Journal of Clinical Ultrasound · doi:10.1002/jcu.20382 · Cited by 5
Cited by
Buijtendijk, M. F., Bet, B. B., Leeflang, M. M., Shah, H., Reuvekamp, T., Goring, T., Docter, D., Timmerman, M. G., Dawood, Y., Lugthart, M. A., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014715.pub2 · Cited by 47
Metadata
- Authors
- Alldred, S. K., Takwoingi, Y., Guo, B., Pennant, M., Deeks, J. J., Neilson, J. P., & Alfirevic, Z.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-03-15
- Volume
- 2017
- Issue
- 3
- Pages
- CD012599-CD012599
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2641583777
- Cited by
- 529
- References
- 246
- FWCI
- 131.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.